The E100: Biotech execs are bullish about 2017, but fret about drug pricing and the FDA under Trump
About the Endpoints 100: This is our second biotech industry survey, which we sent out to our invite-only group of executives on February 6 …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
